The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger.

The media queen also confessed that she was reluctant to take a GLP-1 drug because she felt it was “the easy way out.” That changed after a special on weight loss with experts and clinicians that she taped in July 2023. The panel discussion left her with her “biggest aha moment” about the medication.

As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has uncovered neurological and behavioral health benefits amid risks for pancreatitis and kidney disease.

The findings, based on an analysis of records from 2.5 million VA patients, support much of what scientists already suspected but contain surprises, too.

GLP-1 medications linked to a lower risk of dementia and addiction but higher risk of kidney, pancreatic, and gastrointestinal issues. Demand for weight-loss medications, including popular brands like Ozempic and Wegovy,

T he newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ways they affect the body—both helpful and harmful—beyond reducing weight. In report published in Nature Medicine,

Novo Nordisk (NVO) stock gains on promising Phase 1/2 data for the drugmaker's new weight loss drug amycretin. Read more here.

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their weight in 36 weeks, according to early-stage trial results on Friday, boosting the drugmaker's shares.

Novo Nordisk shares rose sharply after the Danish pharmaceutical giant said an experimental weight-loss shot helped patients lose 22% of their bodyweight in a clinical trial.